Canaccord Genuity analyst John Newman maintained a Buy rating on Delcath Systems (DCTH – Research Report) today and set a price target of $21.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
John Newman has given his Buy rating due to a combination of factors highlighting Delcath Systems’ unique position in the biotech market. The company stands out as a small-cap biotech firm that is not only generating growing revenues but is also profitable, with expectations of becoming cash flow positive soon. This is particularly noteworthy as only a small percentage of biotech companies achieve both positive earnings per share and cash flow.
Moreover, Delcath’s ongoing CHOPIN study, which is expected to yield positive results in the third quarter of 2025, is anticipated to drive increased revenues for its Hepzato treatment. The study’s findings will likely be presented at a significant oncology conference, further boosting Hepzato’s market potential. Additionally, Delcath is exploring large revenue opportunities in liver metastases treatments related to colorectal and breast cancer, supporting a long-term growth trajectory. These factors, combined with an expected cash flow positivity by the first quarter of 2025, underpin Newman’s confidence in maintaining a Buy rating with a $21 price target.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DCTH in relation to earlier this year.